WO2010000580A2 - Use of rooibos or rooibos extracts with prebiotics for skin and hair - Google Patents
Use of rooibos or rooibos extracts with prebiotics for skin and hair Download PDFInfo
- Publication number
- WO2010000580A2 WO2010000580A2 PCT/EP2009/057118 EP2009057118W WO2010000580A2 WO 2010000580 A2 WO2010000580 A2 WO 2010000580A2 EP 2009057118 W EP2009057118 W EP 2009057118W WO 2010000580 A2 WO2010000580 A2 WO 2010000580A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- accordance
- rooibos
- hair
- composition
- Prior art date
Links
- 240000006914 Aspalathus linearis Species 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 208000017520 skin disease Diseases 0.000 claims abstract description 12
- 230000032683 aging Effects 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 10
- 208000025309 Hair disease Diseases 0.000 claims abstract description 8
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims abstract description 8
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 6
- 230000037303 wrinkles Effects 0.000 claims abstract description 5
- 230000006750 UV protection Effects 0.000 claims abstract description 4
- 230000003646 hair health Effects 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 230000036559 skin health Effects 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 230000007613 environmental effect Effects 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 36
- 235000012984 Aspalathus linearis Nutrition 0.000 claims description 25
- 235000003884 Aspalathus contaminatus Nutrition 0.000 claims description 20
- 229920001542 oligosaccharide Polymers 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims description 13
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000013325 dietary fiber Nutrition 0.000 claims description 3
- 230000003803 hair density Effects 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- -1 xylo-oligosacchahdes Polymers 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000037067 skin hydration Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 28
- 235000013361 beverage Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 244000299461 Theobroma cacao Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 235000020330 rooibos tea Nutrition 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- LGTHRBXRBOVOKE-UHFFFAOYSA-N 1-(furan-2-yl)-n-(furan-2-ylmethyl)methanamine Chemical class C=1C=COC=1CNCC1=CC=CO1 LGTHRBXRBOVOKE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241001406038 Lactobacillus johnsonii NCC 533 Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019904 Raftiline® Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000015116 cappuccino Nutrition 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 description 1
- 235000015428 diosmetin Nutrition 0.000 description 1
- 229960001876 diosmetin Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- 235000002677 phytofluene Nutrition 0.000 description 1
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 description 1
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to the use of rooibos or rooibos extract in combination with at least one prebiotic for improving skin or hair health by preventing, alleviating or treating skin or hair disorders or damages such as is effected by inflammatory reactions, environmental factors, ageing or cancer. It can also be used to improve UV protection or skin glow or reduce skin wrinkles or skin inflammation. It also relates to the compositions containing rooibos or rooibos extracts and at least one prebiotic.
- the most prominent epithelial tissue in living beings is the skin, which represents the largest organ in the organism.
- the system of skin integument which comprises the epidermis, dermis and the stratum corneum, correlates with those of internal organs and concurrently interacts with the surroundings. Being the interface between the environment and organism itself, the skin is heavily influenced by external factors and also variable parameters of the organism's inner system.
- the skin's regulative mechanisms need, therefore, always be active to induce systemic changes necessary to maintain normal pathological events concerning skin integument morphology and activities.
- the cutaneous barrier is exposed daily to chemicals, xenobiotic and particles composing urban pollution.
- atmospheric pollutants likely to exert noxious effects on the skin and the hair, three main categories can be distinguished. They are essentially gas, heavy metals, and particles which are the residues of combustion on which are adsorbed many organic compounds. The gases contribute more particularly to the formation of an environment "pro-oxidant" to which the most external surface tissues are directly exposed.
- the oxidation and the degradation of the lipids of the stratum corneum can deteriorate the function barrier of the stratum corneum.
- the disturbance of the external lipids and the architecture of proteins are factors starting in many dermatoses (psoriasis, atopic dermatitis, irritating dermatitis).
- a significant oxidative attack on the level of the surface layers of the stratum can initiate subjacent localised inflammatory processes.
- This deterioration of the cutaneous barrier can be in particular translated for a subject by feelings of cutaneous discomfort, phenomena sensory and/or the demonstration of undesirable cutaneous signs, even painful such as irritations.
- the above mentioned signs of discomfort can be moreover associated with undesirable cutaneous signs, such as rednesses, irritations, scabs, erythemas inflammatory, oedemas and/or buttons.
- EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.
- an object of the present invention is to provide J
- compositions that may be used over a long period of time by humans or pets, and susceptible to be provided in the form of a nutritional supplement, a food or petfood composition or a beverage.
- the present inventors were surprised to see that they could achieve this object by using Rooibos or Rooibos extract, in particular in combination with prebiotics.
- Rooibos, Oriental bush is a wild South African plant that grows in a specific area of the south-western part of South Africa, and that is commonly used by local populations to prepare infusion in the same manner as tea. It is a member of the legume family of plants which scientific name is Aspalathus linearis. Rooibos tea is often called South African red tea or simply red tea or bush tea. Rooibos tea has been popular in South Africa for generations, but is recently consumed increasingly in countries all over the world.
- the present invention relates to an orally administrable composition
- an orally administrable composition comprising Aspalathus linearis or an extract thereof in combination with at least one prebiotic.
- composition comprising Aspalathus linearis or an extract thereof in combination with at least one prebiotic.
- a product for the preparation of a product to improve skin or hair health, treat, alleviate and/or prevent skin or hair disorders.
- the skin disorders or damages that can be treated, alleviated or prevented according to the present invention can for example be selected from the group consisting of skin inflammation, such as UV or chemical-induced skin inflammation, reactive or dry skin, psoriasis, vitiligo, acne, ageing, UV protection, photo ageing, wrinkles. It also provides beneficial effects on skin glow or skin moisture, hydration of the skin.
- the hair (or coat) disorders or damages that can be treated or prevented are hair and coat gloss, hair density, color, oilness, ameliorating hair fiber diameter, sebum production, glossiness and preventing hair and coat loss.
- the composition according to the present invention is administered to a human or to an animal, for ameliorating antioxidant status or barrier function of the skin.
- suitable extracts of Aspalathus linearis may be prepared by any means that are known in the art, e.g., by steam extraction, solvent extraction, distillation, pressing or grinding.
- the extract is obtainable, in particular obtained, by extraction with a solvent from Aspalathus linearis plant material, in particular by a water extraction or an alcohol/water extraction, for example by a ethanol/water extraction.
- the Aspalathus linearis extracts may also be obtainable, and are in particularly obtained by a method comprising the steps of: i) mixing and milling Aspalathus linearis material in milk or a milk protein-containing liquid medium, ii) optionally separating insoluble material to obtain an aqueous suspension iii) optionally pasteurising the resulting suspension iv) optionally add synthetic or natural bioactive components during the processing v) and further optionally drying the suspension to obtain a powder.
- This process has the advantage of being natural and cost effective enabling improved delivery of multi-nutrients in the form of a combination of stabilized water- and fat-soluble compounds in their natural compositions, free of organic solvent residues.
- an extract of Aspalathus linearis is used in the present invention it is preferred if at least 50wt.-%, preferably at least 70 wt.-% more preferably at least 95 wt.-% of the extract are water soluble. This has the advantage that the extract can easily be admixed with other water based foodstuffs before consumption.
- One typical example of an extract of Aspalathus linearis that can be used in the framework of the present invention is rooibos tea.
- Suitable extracts of Aspalathus linearis for the purpose of the present invention are also extracts that are commercially available, such as for example Rooibos from Afriplex or Rooibos from Rooibos Ltd.
- the product also contain at least one prebiotic.
- prebiotic means food substances that promote the growth of probiotics in the intestines. They are not broken down in the stomach and/or upper intestine or absorbed in the Gl tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics.
- Prebiotics are known to produce a synergistic effect with probiotics, thus the combination of probiotics, prebiotics and Aspalathus linearis or an extract thereof will also be very effective in treating or preventing inflammatory disorders.
- the prebiotics that may be used in accordance with the present inventions are not particularly limited and include all food substances that promote the growth of probiotics in the intestines.
- oligosaccharides optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof.
- the prebiotic is preferably in an amount of 0.3 to 10 % dry weight of the composition.
- prebiotics include certain oligosaccharides, such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS).
- FOS fructooligosaccharides
- GOS galactooligosaccharides
- a combination of prebiotics may be used, such as 90% GOS with 10% short chain fructooligosaccharides such as the product sold under the trade mark Raftilose® or 10% inulin such as the product sold under the trade mark Raftiline®.
- Preferred prebiotics are fructo-oligosaccharides (FOS), galacto-oligosacchahdes (IOS), isomalto-oligosacchahdes, xylo-oligosaccharides, oligosaccharides of soy, glycosylsucrose (GS), lactosucrose (LS), lactulose (LA), palatinose-oligosaccharides (PAO), malto-oligosacchahdes (MOS), gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
- FOS fructo-oligosaccharides
- IOS galacto-oligosacchahdes
- IOS isomalto-oligosacchahdes
- xylo-oligosaccharides oligosaccharides of soy
- glycosylsucrose GS
- lactosucrose LS
- LA lactosucrose
- LA lac
- a particularly preferred prebiotic is a mixture of galacto-oligosacchahde(s), N- acetylated oligosacchahde(s) and sialylated oligosaccharide(s) in which the N- acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosacchahde(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture.
- This mixture is hereinafter referred to as "CMOS-GOS”.
- a composition for use according to the invention contains from 2.5 to 15.0 wt% CMOS- GOS on a dry matter basis with the proviso that the composition comprises at least 0.02 wt% of an N-acetylated oligosaccharide, at least 2.0 wt% of a galacto- oligosaccharide and at least 0.04 wt% of a sialylated oligosaccharide.
- the product comprising a composition comprising Aspalathus linearis or an extract thereof and a prebiotic according to the present invention may be for example a food product, a drink, a food supplement, a nutraceutical, a pet food product or a medicament.
- the product may also further comprise a protein source, a carbohydrate source, a lipid source, a mineral source and/or a vitamin source.
- a protein source a carbohydrate source
- a lipid source a mineral source and/or a vitamin source.
- proteins, carbohydrates, lipids, minerals and/or vitamins may have several advantages. These compounds generally contribute to the taste and mouthfeel of the final product. They also provide the body with nutrients that it may need urgently when it is affected by skin/hair disorders. They also allow formulating the product of the present invention as a complete nutritional formula, so that no additional nutrition is needed. This might be in particularly helpful for consumers that do not ingest sufficient amounts of food or that have trouble swallowing and that hence wish to ingest only small amounts of food.
- the products used in the present invention are preferably intended for enteral application. While the products are primarily intended to be used by humans, they may also be applied to animals, in particular companion animals, pets or livestock.
- Particularly preferred products are products selected from the group consisting of teas, iced teas, a foamed beverage, a confectionery product, a culinary product, a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, a product for lactating mothers, a liquid drink, a soup, a dietary supplement, a meal replacement, a nutritional bar, a milk or a fermented milk product, a yoghurt, a milk based powder, an enteral nutrition product, an infant formula, an infant nutritional product, a puree, a cereal product or a fermented cereal based product, an ice-cream, candy, sweets, biscuits, cakes, a chocolate, a cappuccino, a coffee, a culinary product such as mayonnaise, tomato puree or salad dressings, a pet food, a pet beverage, a tablet, a capsule, a pill, a solution, a suspension, a syrup, a powder, a gel, a dried oral supplement or a we
- Aspalathus linearis or an extract thereof and prebiotic in the product will depend on several factors, such as the nature of the extract, the condition of the plant, the age, condition and size of the person or animal to be treated, the frequency, the product will be applied and/or the specific kind of skin/hair disorder or damage to be treated or prevented.
- the effectiveness of the composition according to the present invention is generally dose dependant and follows a dose response curve. If generally mild skin/hair disorders or damages are to be prevented and the product will be used frequently, very small amounts of the composition will be sufficient to achieve the desired effect. If a severe skin disorder is to be treated, larger amounts of the composition will be more appropriate, although also small amounts will produce an effect.
- the product contains Aspalathus linearis or an extract thereof in an amount in the range of about 0,1 g/l to 10 g/l, preferably in the range of 0,5 g/l to 3 g/l product. If the total amount of product cannot be measured in litres it is preferred if the product contains Aspalathus linearis or an extract thereof in an amount in the range of about 0,1 g/kg to 10 g/kg, preferably in the range of 0,5 g/kg to 3 g/kg product.
- the product contains Aspalathus linearis or an extract thereof in a daily dose of 0,01 g-100g, preferably 0,25 g-10g.
- the fibre content is between 2 and 40 g/l of the composition as consumed, more preferably between 4 and 10 g/l.
- the product may also comprises at least one kind of food grade micro-organism, in particular probiotics.
- Food grade are all substances that are approved for human or animal consumption.
- Probiotic means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host.
- the probiotics may be selected from the group consisting of group consisting of Bifidobacterium, Lactobacillus, Streptococcus and Saccharomyces or mixtures thereof, in particular selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivahus, Streptococcus faecium, Saccharomyces boulardii and Lactobacillus reuteri or mixtures thereof, preferably selected from the group consisting of Lactobacillus johnsonii NCC 533 (CNCM 1-1225), Bifidobacterium longum NCC 490 (CNCM 1-2170), Bifidobacterium longum NCC 2705 (CNCM 1-2618) , Bifidobacterium lactis B
- probiotics in a composition comprising Aspalathus linearis or an extract thereof may have several important effects. Consequently, the combination of probiotics with Aspalathus linearis or an extract thereof can be expected to have a further positive effect on the treatment and prevention of skin/hair disorders or damages.
- the product prepared for the use of the present invention may also contain at least one phytonutrient.
- phytonutrient describes those plant compounds which have health- protecting qualities. For example antioxidant, immune boosting or other health promoting properties of active compounds in plants are typical effects of phytonutrients.
- Phytonuthents include but are not limited to terpenes, carotenoids, limonoids, polyphenols, and phytosterols.
- the carotenoids may be selected from the group consisting of carotenes and xanthophylls such as lycopene, carotene, phytofluene, phytoene, canthaxanthin, beta-cryptoxanthin, capsanthin, lutein, zeaxanthin, or those in the form of fatty acid esters, or mixtures thereof.
- the polyphenols are preferably selected from the group consisting of flavones such as apigenin, luteolin or diosmetin, flavonols such as quercetin, myricetin, kaempferol, flavanones, anthocyanidins or isoflavones such as genistein, daidzein, or phenolic acids such as caffeic, ferulic acid or mixtures thereof.
- Preferred phytonutrients for the present invention are beta-carotene, lutein, and/or catechin.
- the phytonutrients may be also provided in the form of a plant or plant extract.
- Rooibos is added to the other ingredients as Rooibos extract powder.
- "Rooibos" refers to Rooibos extract.
- This Rooibos sweetening powder is obtained by the following preparation process, comprising the steps of, in order: (i) mixing 100g Rooibos dried leaves and stems with 1 litre boiling water,
- Powdered beverage composition comprising cereals, fruit powder and/or bits, and/or chocolate ingredients are prepared that incorporate an extract of Rooibos plant. They are formulated as follows (quantities are given in % of total weight of the composition):
- Example 2 Confectionery and chocolate compositions can also be prepared, that incorporate Rooibos. Examples of such food compositions are as follows (quantities are given in % of total weight of the final composition).
- a cereal beverage composition is prepared that incorporates a sweetening ingredient from Rooibos plant.
- the said food composition comprises (quantities are given in % of total weight of the composition):
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to the use of rooibos or rooibos extract in combination with at least one prebiotic for improving skin or hair health by preventing, alleviating or treating skin or hair disorders or damages such as is effected by inflammatory reactions, environmental factors, ageing or cancer. It can also be used to improve UV protection or skin glow or reduce skin wrinkles or skin inflammation. It also relates to the compositions containing rooibos or rooibos extracts and at least one prebiotic.
Description
Use of Rooibos or Rooibos extracts with prebiotics for skin and hair
The present invention relates to the use of rooibos or rooibos extract in combination with at least one prebiotic for improving skin or hair health by preventing, alleviating or treating skin or hair disorders or damages such as is effected by inflammatory reactions, environmental factors, ageing or cancer. It can also be used to improve UV protection or skin glow or reduce skin wrinkles or skin inflammation. It also relates to the compositions containing rooibos or rooibos extracts and at least one prebiotic.
Background of the Invention
The most prominent epithelial tissue in living beings is the skin, which represents the largest organ in the organism. The system of skin integument, which comprises the epidermis, dermis and the stratum corneum, correlates with those of internal organs and concurrently interacts with the surroundings. Being the interface between the environment and organism itself, the skin is heavily influenced by external factors and also variable parameters of the organism's inner system. The skin's regulative mechanisms need, therefore, always be active to induce systemic changes necessary to maintain normal pathological events concerning skin integument morphology and activities.
A great deal of processes assuring the adequate consumption of increased affluence of energetic and plastic substances according to the skin's needs become guarantors of morphological and functional stability of skin structures. So, the state of integuments determines the realization of metabolic processes necessary for skin cell viability and activity leading to the presence of healthy skin peculiarities such as barrier function, elasticity, turgor properties, humidity or pigmentation, for example.
During the lifetime of a living being different signs, characteristic of ageing, appear on the skin or hair, with the principal clinical signs being the appearance of fine lines and deep wrinkles which increase or are accentuated with age, loss of hair, reduced hair density, glossiness, color, oilness, fiber diameter, for example.
These signs of ageing are even promoted by exposure of the skin and hair to exogenous influences, such as e.g. UV-radiation, pollutants, free radicals or chemical substances.
Moreover, the cutaneous barrier is exposed daily to chemicals, xenobiotic and particles composing urban pollution. Among these atmospheric pollutants likely to exert noxious effects on the skin and the hair, three main categories can be distinguished. They are essentially gas, heavy metals, and particles which are the residues of combustion on which are adsorbed many organic compounds. The gases contribute more particularly to the formation of an environment "pro-oxidant" to which the most external surface tissues are directly exposed.
The oxidation and the degradation of the lipids of the stratum corneum can deteriorate the function barrier of the stratum corneum. The disturbance of the external lipids and the architecture of proteins are factors starting in many dermatoses (psoriasis, atopic dermatitis, irritating dermatitis). In addition, a significant oxidative attack on the level of the surface layers of the stratum can initiate subjacent localised inflammatory processes. This deterioration of the cutaneous barrier can be in particular translated for a subject by feelings of cutaneous discomfort, phenomena sensory and/or the demonstration of undesirable cutaneous signs, even painful such as irritations. The above mentioned signs of discomfort can be moreover associated with undesirable cutaneous signs, such as rednesses, irritations, scabs, erythemas inflammatory, oedemas and/or buttons.
In the art several means have been proposed to prevent destructive effects of environment or ageing on skin epithelial cells. For example, means to prevent skin deterioration or ageing is to provide compounds scavenging free radicals. In this respect EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.
Although there is a great diversity of active compounds for ameliorating skin and hair or coat health, there still exists a need in the art to provide new active compounds, naturally occurring. In particular, an object of the present invention is to provide
J
compositions that may be used over a long period of time by humans or pets, and susceptible to be provided in the form of a nutritional supplement, a food or petfood composition or a beverage.
Summary of the invention
The present inventors were surprised to see that they could achieve this object by using Rooibos or Rooibos extract, in particular in combination with prebiotics.
Rooibos, Afrikaans for "red bush"; is a wild South African plant that grows in a specific area of the south-western part of South Africa, and that is commonly used by local populations to prepare infusion in the same manner as tea. It is a member of the legume family of plants which scientific name is Aspalathus linearis. Rooibos tea is often called South African red tea or simply red tea or bush tea. Rooibos tea has been popular in South Africa for generations, but is recently consumed increasingly in countries all over the world.
Thus, the present invention relates to an orally administrable composition comprising Aspalathus linearis or an extract thereof in combination with at least one prebiotic.
It also relates to an orally administrable composition comprising Aspalathus linearis or an extract thereof in combination with at least one prebiotic. for the preparation of a product to improve skin or hair health, treat, alleviate and/or prevent skin or hair disorders.
The skin disorders or damages that can be treated, alleviated or prevented according to the present invention can for example be selected from the group consisting of skin inflammation, such as UV or chemical-induced skin inflammation, reactive or dry skin, psoriasis, vitiligo, acne, ageing, UV protection, photo ageing, wrinkles. It also provides beneficial effects on skin glow or skin moisture, hydration of the skin.
The hair (or coat) disorders or damages that can be treated or prevented are hair and coat gloss, hair density, color, oilness, ameliorating hair fiber diameter, sebum production, glossiness and preventing hair and coat loss.
Also, the composition according to the present invention is administered to a human or to an animal, for ameliorating antioxidant status or barrier function of the skin.
Detailed Description of the Invention
In a particular preferred embodiment of the present invention, suitable extracts of Aspalathus linearis may be prepared by any means that are known in the art, e.g., by steam extraction, solvent extraction, distillation, pressing or grinding.
It is however preferred if the extract is obtainable, in particular obtained, by extraction with a solvent from Aspalathus linearis plant material, in particular by a water extraction or an alcohol/water extraction, for example by a ethanol/water extraction.
The use of water as extraction medium has the advantage that the obtained product can be directly incorporated into final products without having to eliminate the extraction medium first.
The traditional process to prepare infusible leaves out of Rooibos plants was as follows: plants are harvested by cutting their stems and leaves which are then put in a heap. The temperature inside the heap rapidly raises up to 400C, which causes fermentation of the leaves. After about one day, the leaf and stem pieces are dried in the sun and sieved, ready for infusion. This process is progressively replaced by batch rotary fermentation of moistened leaves and stems, after which a sun-drying step is still preferred. The infusion is then prepared in large quantities which are filtered and concentrated. Preferably after further purification, the ingredient is then ready to be added to any food preparation.
The Aspalathus linearis extracts may also be obtainable, and are in particularly obtained by a method comprising the steps of: i) mixing and milling Aspalathus linearis material in milk or a milk protein-containing liquid medium, ii) optionally separating insoluble material to obtain an aqueous suspension iii) optionally pasteurising the resulting suspension iv) optionally add synthetic or natural bioactive
components during the processing v) and further optionally drying the suspension to obtain a powder.
This process has the advantage of being natural and cost effective enabling improved delivery of multi-nutrients in the form of a combination of stabilized water- and fat-soluble compounds in their natural compositions, free of organic solvent residues.
If an extract of Aspalathus linearis is used in the present invention it is preferred if at least 50wt.-%, preferably at least 70 wt.-% more preferably at least 95 wt.-% of the extract are water soluble. This has the advantage that the extract can easily be admixed with other water based foodstuffs before consumption.
One typical example of an extract of Aspalathus linearis that can be used in the framework of the present invention is rooibos tea.
Suitable extracts of Aspalathus linearis for the purpose of the present invention are also extracts that are commercially available, such as for example Rooibos from Afriplex or Rooibos from Rooibos Ltd.
The product also contain at least one prebiotic. "Prebiotic" means food substances that promote the growth of probiotics in the intestines. They are not broken down in the stomach and/or upper intestine or absorbed in the Gl tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics.
Prebiotics are known to produce a synergistic effect with probiotics, thus the combination of probiotics, prebiotics and Aspalathus linearis or an extract thereof will also be very effective in treating or preventing inflammatory disorders.
The prebiotics that may be used in accordance with the present inventions are not particularly limited and include all food substances that promote the growth of probiotics in the intestines.
Preferably, they may be selected from the group consisting of oligosaccharides,
optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof. The prebiotic is preferably in an amount of 0.3 to 10 % dry weight of the composition.
Further examples of prebiotics include certain oligosaccharides, such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS). A combination of prebiotics may be used, such as 90% GOS with 10% short chain fructooligosaccharides such as the product sold under the trade mark Raftilose® or 10% inulin such as the product sold under the trade mark Raftiline®.
Preferred prebiotics are fructo-oligosaccharides (FOS), galacto-oligosacchahdes (IOS), isomalto-oligosacchahdes, xylo-oligosaccharides, oligosaccharides of soy, glycosylsucrose (GS), lactosucrose (LS), lactulose (LA), palatinose-oligosaccharides (PAO), malto-oligosacchahdes (MOS), gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
A particularly preferred prebiotic is a mixture of galacto-oligosacchahde(s), N- acetylated oligosacchahde(s) and sialylated oligosaccharide(s) in which the N- acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosacchahde(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. This mixture is hereinafter referred to as "CMOS-GOS". Preferably, a composition for use according to the invention contains from 2.5 to 15.0 wt% CMOS- GOS on a dry matter basis with the proviso that the composition comprises at least 0.02 wt% of an N-acetylated oligosaccharide, at least 2.0 wt% of a galacto- oligosaccharide and at least 0.04 wt% of a sialylated oligosaccharide.
The product comprising a composition comprising Aspalathus linearis or an extract thereof and a prebiotic according to the present invention may be for example a food product, a drink, a food supplement, a nutraceutical, a pet food product or a medicament.
The product may also further comprise a protein source, a carbohydrate source, a lipid source, a mineral source and/or a vitamin source. The presence of proteins,
carbohydrates, lipids, minerals and/or vitamins may have several advantages. These compounds generally contribute to the taste and mouthfeel of the final product. They also provide the body with nutrients that it may need urgently when it is affected by skin/hair disorders. They also allow formulating the product of the present invention as a complete nutritional formula, so that no additional nutrition is needed. This might be in particularly helpful for consumers that do not ingest sufficient amounts of food or that have trouble swallowing and that hence wish to ingest only small amounts of food.
Consequently, the products used in the present invention are preferably intended for enteral application. While the products are primarily intended to be used by humans, they may also be applied to animals, in particular companion animals, pets or livestock.
Particularly preferred products are products selected from the group consisting of teas, iced teas, a foamed beverage, a confectionery product, a culinary product, a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, a product for lactating mothers, a liquid drink, a soup, a dietary supplement, a meal replacement, a nutritional bar, a milk or a fermented milk product, a yoghurt, a milk based powder, an enteral nutrition product, an infant formula, an infant nutritional product, a puree, a cereal product or a fermented cereal based product, an ice-cream, candy, sweets, biscuits, cakes, a chocolate, a cappuccino, a coffee, a culinary product such as mayonnaise, tomato puree or salad dressings, a pet food, a pet beverage, a tablet, a capsule, a pill, a solution, a suspension, a syrup, a powder, a gel, a dried oral supplement or a wet oral supplement.
The amounts of Aspalathus linearis or an extract thereof and prebiotic in the product will depend on several factors, such as the nature of the extract, the condition of the plant, the age, condition and size of the person or animal to be treated, the frequency, the product will be applied and/or the specific kind of skin/hair disorder or damage to be treated or prevented.
The present inventors have found that the effectiveness of the composition according to the present invention is generally dose dependant and follows a dose response
curve. If generally mild skin/hair disorders or damages are to be prevented and the product will be used frequently, very small amounts of the composition will be sufficient to achieve the desired effect. If a severe skin disorder is to be treated, larger amounts of the composition will be more appropriate, although also small amounts will produce an effect.
Generally, it is preferred if the product contains Aspalathus linearis or an extract thereof in an amount in the range of about 0,1 g/l to 10 g/l, preferably in the range of 0,5 g/l to 3 g/l product. If the total amount of product cannot be measured in litres it is preferred if the product contains Aspalathus linearis or an extract thereof in an amount in the range of about 0,1 g/kg to 10 g/kg, preferably in the range of 0,5 g/kg to 3 g/kg product.
Preferably the product contains Aspalathus linearis or an extract thereof in a daily dose of 0,01 g-100g, preferably 0,25 g-10g.
Preferably, if the prebiotic is in the form of dietary fiber, the fibre content is between 2 and 40 g/l of the composition as consumed, more preferably between 4 and 10 g/l.
The product may also comprises at least one kind of food grade micro-organism, in particular probiotics.
"Food grade" are all substances that are approved for human or animal consumption.
"Probiotic" means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host.
For the purpose of the present invention, the probiotics may be selected from the group consisting of group consisting of Bifidobacterium, Lactobacillus, Streptococcus and Saccharomyces or mixtures thereof, in particular selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivahus, Streptococcus faecium, Saccharomyces boulardii and Lactobacillus reuteri or mixtures thereof, preferably selected from the group
consisting of Lactobacillus johnsonii NCC 533 (CNCM 1-1225), Bifidobacterium longum NCC 490 (CNCM 1-2170), Bifidobacterium longum NCC 2705 (CNCM 1-2618) , Bifidobacterium lactis Bb12, Bifidobacterium lactis NCC2818 (CNCM I-3446), Lactobacillus paracasei NCC 2461 (CNCM 1-2116), Lactobacillus rhamnosus GG, Lactobacillus rhamnosus NCC4007 (CGMCC 1.3724) Enterococcus faecium SF 68 (NCIMB 10415), and mixtures thereof.
The presence of probiotics in a composition comprising Aspalathus linearis or an extract thereof may have several important effects. Consequently, the combination of probiotics with Aspalathus linearis or an extract thereof can be expected to have a further positive effect on the treatment and prevention of skin/hair disorders or damages.
Finally, the product prepared for the use of the present invention may also contain at least one phytonutrient.
The term "phytonutrient" describes those plant compounds which have health- protecting qualities. For example antioxidant, immune boosting or other health promoting properties of active compounds in plants are typical effects of phytonutrients. Phytonuthents include but are not limited to terpenes, carotenoids, limonoids, polyphenols, and phytosterols.
The carotenoids may be selected from the group consisting of carotenes and xanthophylls such as lycopene, carotene, phytofluene, phytoene, canthaxanthin, beta-cryptoxanthin, capsanthin, lutein, zeaxanthin, or those in the form of fatty acid esters, or mixtures thereof.
The polyphenols are preferably selected from the group consisting of flavones such as apigenin, luteolin or diosmetin, flavonols such as quercetin, myricetin, kaempferol, flavanones, anthocyanidins or isoflavones such as genistein, daidzein, or phenolic acids such as caffeic, ferulic acid or mixtures thereof.
Preferred phytonutrients for the present invention are beta-carotene, lutein, and/or catechin. The phytonutrients may be also provided in the form of a plant or plant extract.
It is clear to those of skill in the art that they can freely combine all features described herein without departing from the scope of the present invention as disclosed.
Further advantages and features of the present invention are apparent from the following examples.
For examples 1 and 2 below, Rooibos is added to the other ingredients as Rooibos extract powder. In all example compositions, "Rooibos" refers to Rooibos extract.
This Rooibos sweetening powder is obtained by the following preparation process, comprising the steps of, in order: (i) mixing 100g Rooibos dried leaves and stems with 1 litre boiling water,
(ii) infusing the mix for about 5 minutes, and then
(iii) discarding solids from the infusion so as to obtain a liquid beverage containing about 10 g/l of Rooibos dry matter, (iv) removing water so as to obtain a dry extract powder.
Example 1 :
Powdered beverage composition comprising cereals, fruit powder and/or bits, and/or chocolate ingredients are prepared that incorporate an extract of Rooibos plant. They are formulated as follows (quantities are given in % of total weight of the composition):
- Rooibos dry matter between 0 and 80 %
- Cocoa between 5 and 40 % - Maltodextrine between 0 and 80 %
- Flavours, vitamins and Lecithin 1-5 %
- Sugar between 0 and 80%
Example 2:
Confectionery and chocolate compositions can also be prepared, that incorporate Rooibos. Examples of such food compositions are as follows (quantities are given in % of total weight of the final composition).
For chewing gum:
- gum base from 20 to 35%
- gum acacia solution from 5 to 15%
- sorbitol from 40 to 50% - mannitol from 10 to 20%
- Rooibos from 10 to 35%
- Flavour from 0.001 to 1 %
- Artificial sweeteners from 0 to 2%
For a low-sugar chocolate:
- Cocoa mass from 35 to 45%
- Cocoa butter from 10 to 20%
- erythritol from 40 to 53% - Rooibos from 0.02 to 10%
- Lecithin from 0.1 to 1 %
- Vanillin from 0.01 to 0.03%
Example 3
A cereal beverage composition is prepared that incorporates a sweetening ingredient from Rooibos plant. The said food composition comprises (quantities are given in % of total weight of the composition):
- Cereal beverage (eg. Ecco® or OrzoroCaro® 6% to 99%
- Others (aromas, nutriments) 0.5% to 10%
- Rooibos 0.04% to 0.8%
Claims
1. An orally ingestible composition comprising Aspalathus linearis or an extract thereof and at least one prebiotic.
2. A composition in accordance with claim 1 characterized in that the prebiotic is selected from the group consisting of oligosaccharides, optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof.
3. A composition in accordance with claim 1 characterized in that the prebiotic is fructo-oligosaccharides (FOS), galacto-oligosacchahdes (IOS), isomalto- oligosaccharides, xylo-oligosacchahdes, oligosaccharides of soy, glycosylsucrose (GS), lactosucrose (LS), lactulose (LA), palatinose-oligosacchahdes (PAO), malto- oligosaccharides (MOS), gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
4. A composition in accordance with one of the preceding claims, wherein the extract is obtainable by extraction with a solvent from Aspalathus linearis plant material, in particular by a water extraction or an alcohol/water extraction, for example by a ethanol/water extraction.
5. A composition in accordance with one of the preceding claims, wherein at least 50wt.-%, preferably at least 70 wt.-% more preferably at least 95 wt.-% of the extract are water soluble.
6. A composition in accordance with one of the preceding claims, wherein the extract is a commercially available extract, preferably Rooibos from Afhplex or Rooibos from Rooibos Ltd.
7. A composition in accordance with one of the preceding claims, which further comprises a protein source, a carbohydrate source, a lipid source, a mineral source and/or a vitamin source and is for oral, enteral and/or parenteral application.
8. A composition in accordance with one of the preceding claims, which comprises at least one kind of food grade micro-organisms, in particular probiotics selected from the group consisting of group consisting of Bifidobacterium, Lactobacillus, Streptococcus and Saccharomyces or mixtures thereof.
9. Use of a composition according to claim 1 , for the preparation of an orally administrable product for improving skin or hair health by preventing, alleviating or treating skin or hair disorders or damages such as is effected by inflammatory reactions, environmental factors, ageing or cancer.
10. Use in accordance with claim 9, wherein the skin disorder or damage is selected from the group consisting of skin inflammation, reactive or dry skin, psoriasis, vitiligo, acne, ageing, UV protection, photo ageing, wrinkles, skin glow or skin hydration or moisture of the skin.
11. Use in accordance with claim 9, wherein the hair or coat disorder or damage is selected from the group consisting of hair and coat gloss, hair density, color, oilness, ameliorating hair fiber diameter, sebum production, glossiness and preventing hair and coat loss.
12. Use in accordance with one of the preceding claims, wherein the product is a food product, a drink, a food supplement, a nutraceutical, a pet food product or a medicament.
13. Use in accordance with one of the preceding claims, wherein the product contains Aspalathus linearis or an extract thereof in an amount in the range of about 0,1 g/l to 10 g/l, preferably in the range of 0,5 g/l to 3 g/l.
14. Use in accordance with one of the preceding claims, wherein the product contains Aspalathus linearis or an extract thereof in a daily dose of 0,01 g-100g, preferably 0,25 g-1 Og.
15. Use in accordance with one of the preceding claims, wherein the product further contains at least one phytonutrient, preferably selected from the group consisting of lutein and catechin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157873.4 | 2008-06-09 | ||
| EP08157873 | 2008-06-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010000580A2 true WO2010000580A2 (en) | 2010-01-07 |
| WO2010000580A3 WO2010000580A3 (en) | 2010-06-24 |
Family
ID=39832581
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2009/057117 WO2010000579A2 (en) | 2008-06-09 | 2009-06-09 | Use of rooibos or rooibos extracts for skin and hair |
| PCT/EP2009/057118 WO2010000580A2 (en) | 2008-06-09 | 2009-06-09 | Use of rooibos or rooibos extracts with prebiotics for skin and hair |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2009/057117 WO2010000579A2 (en) | 2008-06-09 | 2009-06-09 | Use of rooibos or rooibos extracts for skin and hair |
Country Status (1)
| Country | Link |
|---|---|
| WO (2) | WO2010000579A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013530177A (en) * | 2010-06-18 | 2013-07-25 | ネステク ソシエテ アノニム | L. John Sonny La1, B. Longum NCC2705 and immune disorders |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2562302A (en) * | 2017-05-12 | 2018-11-14 | Univ Pretoria | Aspalathus linearis extracts for melanin stimulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041854A2 (en) * | 2003-11-03 | 2005-05-12 | Cortex Technology Aps | Composition for the cosmetic treatment of age-related dermatological symptoms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2742866B2 (en) * | 1993-08-02 | 1998-04-22 | 株式会社日本ルイボスティー本社 | Rooibos Concentrate Extract |
| JPH08133983A (en) * | 1994-11-02 | 1996-05-28 | Asugen Seiyaku Kk | Extract of aspalathus linealis and its use |
| JPH08256707A (en) * | 1995-03-20 | 1996-10-08 | Ichiro Otake | Jelly food of rooibos tea |
| JP3467576B2 (en) * | 1996-05-01 | 2003-11-17 | 株式会社孔葉堂 | SOD-like action antioxidant beverage |
| DE29717497U1 (en) * | 1997-10-01 | 1999-02-04 | Braun, Michaela, Dipl.-Ing., 52064 Aachen | Cosmetic tea extract |
| US20070036742A1 (en) * | 2005-08-09 | 2007-02-15 | Access Business Group International Llc | Methods and compositions for modulating hair growth or regrowth |
| EP1923066A1 (en) * | 2006-11-08 | 2008-05-21 | Cognis IP Management GmbH | Composition comprising rooibos tea and conjugated linoleic acid (CLA) |
| KR100844076B1 (en) * | 2007-08-02 | 2008-07-15 | 리뉴얼라이프(주) | Process for making chunggukjang powder containing dietary fiber and chunggukjang powder thereof |
| JP2009073775A (en) * | 2007-09-21 | 2009-04-09 | Orbis Inc | Composition for oral administration |
-
2009
- 2009-06-09 WO PCT/EP2009/057117 patent/WO2010000579A2/en active Application Filing
- 2009-06-09 WO PCT/EP2009/057118 patent/WO2010000580A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041854A2 (en) * | 2003-11-03 | 2005-05-12 | Cortex Technology Aps | Composition for the cosmetic treatment of age-related dermatological symptoms |
Non-Patent Citations (5)
| Title |
|---|
| DATABASE WPI Week 199516 Thomson Scientific, London, GB; AN 1995-117841 XP002542579 & JP 07 039353 A (RUIBOSUTI JAPAN KK) 10 February 1995 (1995-02-10) * |
| DATABASE WPI Week 199631 Thomson Scientific, London, GB; AN 1996-306481 XP002500594 & JP 08 133983 A (ASUGEN SEIYAKU KK) 28 May 1996 (1996-05-28) * |
| DATABASE WPI Week 199650 Thomson Scientific, London, GB; AN 1996-500304 XP002576752 & JP 08 256707 A (OTAKE I) 8 October 1996 (1996-10-08) * |
| DATABASE WPI Week 200927 Thomson Scientific, London, GB; AN 2009-G80393 XP002576754 & JP 2009 073775 A (ORBIS KK) 9 April 2009 (2009-04-09) * |
| DATABASE WPI Week 200964 Thomson Scientific, London, GB; AN 2009-E18414 XP002576753 & KR 100 844 076 B1 (RENEWALLIFE CO LTD) 15 July 2008 (2008-07-15) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013530177A (en) * | 2010-06-18 | 2013-07-25 | ネステク ソシエテ アノニム | L. John Sonny La1, B. Longum NCC2705 and immune disorders |
| US9937212B2 (en) | 2010-06-18 | 2018-04-10 | Nestec S.A. | L. johnsonii LA1, B. longum NCC2705 and immune disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010000579A3 (en) | 2010-06-24 |
| WO2010000579A2 (en) | 2010-01-07 |
| WO2010000580A3 (en) | 2010-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2399755T5 (en) | Functional Ingredient Administration | |
| EP2133088A2 (en) | Rooibos and inflammation | |
| KR102409377B1 (en) | Composition for improving dry eyes and preventing tear pigmentation for pets | |
| KR101401555B1 (en) | Stable and bioavailable compositions of isomers of lycopene for skin and hair | |
| KR101768806B1 (en) | Composition comprising a fermented Araliaceae plant for anti-inflammation or anti-cancer | |
| KR20190055552A (en) | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| KR20160058389A (en) | Method of Manufacturing Volumizing Antocyanine Probiotics Metabolite and Pharmetics, cosmetics and Juice and food complex | |
| JP5270680B2 (en) | Soybean fermented polymer substance mixed with folic acid and composition containing the same | |
| KR20200089785A (en) | Antimicrobial emulsion compositon comprising yuja seed oil and yuja juice as an active ingredient, use thereof and method preparing the same | |
| WO2010000578A2 (en) | Use of honeybush or honeybush extracts with prebiotics for skin and hair | |
| WO2010000580A2 (en) | Use of rooibos or rooibos extracts with prebiotics for skin and hair | |
| CN115486541B (en) | Herbal probiotic composition with whitening effect and preparation method thereof | |
| KR20200040606A (en) | Composition for anti-oxidation, anti-diabetes, pore shrink or anti-wrinkle comprising extract of Arisoo apple | |
| KR20070022018A (en) | Delivery of functional ingredients | |
| JP2012067082A (en) | Oral composition | |
| KR102144677B1 (en) | Composition for anti-oxidation, anti-inflammation, or anti-wrinkle comprising extract of Greenball apple peel | |
| KR100987517B1 (en) | Biopolymer produced by fermenting the extract of soybean with folic acid and a composition containing thereof | |
| JP7131785B1 (en) | Skin moisturizing agent and skin barrier function improving agent | |
| KR20200040607A (en) | Composition for anti-oxidation, anti-inflammation, anti-diabetes, pore shrink, or anti-wrinkle comprising extract of Summer prince apple | |
| Butnariu | Essential Compounds in Skin Health | |
| Chokli | Cereals | |
| Ninan | Probiotics, prebiotics and synbiotics | |
| Bushaira | Vegetables and Fruits | |
| Begum | Functional Foods | |
| Begum | Pulses and legumes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09772280 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09772280 Country of ref document: EP Kind code of ref document: A2 |